Skye Bioscience Inc.(US:SKYE) Globenewswire·2026-01-15 17:05Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its drug nimacimab during the class period from November 4, 2024, to October 3, 2025 [7]. Allegation Details - The lawsuit claims that Skye's management misrepresented the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [7]. - Specific allegations include that nimacimab was less effective than claimed, leading to misleading public statements about its potential [7]. Stock Impact - Following the announcement of disappointing clinical trial results on October 6, 2025, Skye's stock price dropped by $2.85 per share, or 60%, closing at $1.90 per share [7]. Next Steps - Investors who purchased Skye securities during the class period and suffered losses are encouraged to contact Bragar Eagel & Squire for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 16, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in securities litigation [5]. - The firm operates nationwide and handles cases in both federal and state courts [5].